UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000967
Receipt number R000001165
Scientific Title Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)
Date of disclosure of the study information 2008/01/07
Last modified on 2017/11/30 18:06:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)

Acronym

Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)

Scientific Title

Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)

Scientific Title:Acronym

Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)

Region

Japan


Condition

Condition

Postmenopausal breast cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Postmenopausal breast cancer patients who were relapsed during or within one year after completion of anastorozole treatment received high-dose toremifene,and efficacy and predictive factors were assessed.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

clinical benefit

Key secondary outcomes

1. clinical responce rate
2. progression free survival(PFS)
3. time to progression(TTP)
4. adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Toremifene (120mg) is orally administered once a day everyday.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1. A written consent is obtained
2. Patients diagnosed histologically as having had breast cancer at primary lesion
3. Patients relapsed during or after winthin one year completion of anastrozole treatment
4. PS(ECOG):0-2
5. Patients having measurable lesion or assessable bone lesion
6.
7. Patients with expected lifetime for more than 3 months
8. Patients with bone metastasis without radiotherapy

Key exclusion criteria

1. Patients under anti-estrogen hormone therapy
2. Patients under hormone therapy except for anastrozole
3. Patients diagnosed as inflammatory breast cancer
4. Patients with a history of deep venous thrombosis
5. Patients with serious complications
A. Patients with ischemic heart disease or cardiac arrhythmia that need treatment(left ventricular hypertrophy or mild left ventricular load induced by hypertension,or mild right bundle-branch block is eligible)
B. Patients with a history of myocardial infarction within 6 months onset
C. Patietns with uncontrollable diabetes
6. Patients with brain metastasis
7. Patients taking raloxifen (belonging to SERM) for treatment of osteoporosis
8. Doctor's decision for exclusion

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshio Tabei

Organization

Saitama Cancer Center

Division name

Breast Oncology

Zip code


Address

818 Komuro Ina Kitaadati, Saitama 362-0806

TEL

048-722-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Toshihiro Kai

Organization

Shintoshin Ladies' Mammoclinic

Division name

Saitama Breast Cancer Clinical Study Group Executive office

Zip code


Address

3F,Capital Bldg. 4-261-1,Kishiki-cho,Omiya-ku,Saitama-city ,Saitama 330-0843

TEL

048-600-1722

Homepage URL

http://www.sbccsg.org/

Email

toshikai@sbccsg.org


Sponsor or person

Institute

Saitama Breast Cancer Clinical Study Group (SBCCSG)

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 01 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2007 Year 11 Month 30 Day

Date of IRB


Anticipated trial start date

2008 Year 01 Month 01 Day

Last follow-up date

2013 Year 01 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 01 Month 06 Day

Last modified on

2017 Year 11 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001165


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name